Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Genedata Expressionist® Established as Data Analysis Platform for Oncological Research

Published: Friday, December 28, 2012
Last Updated: Friday, December 28, 2012
Bookmark and Share
carcinoGENOMICS and other EU-funded research consortia help Genedata advance software platform

Genedata, a leading provider of advanced software solutions for drug discovery and life science research, has announced its successful contributions to several oncology-related research consortia, including the EU-funded carcinoGENOMICS, Newgeneris, and INCA projects. Genedata Expressionist, the company's flagship product for molecular profiling applications, was successfully used by these consortia for the analysis and management of complex high-volume, oncology-related data. Additionally, the consortia's oncology-specific requirements fueled the development of enhanced capabilities in Genedata Expressionist, which are now available to all licensees of the software. A comprehensive and enterprise-level solution, Genedata Expressionist helps to identify and understand molecular biomarkers by easily integrating transcriptomics, genomics, epigenomics, proteomics, and metabolomics data.

In implementing Genedata Expressionist for Genomic Profiling, Genedata domain experts worked closely with several EU research consortia including the carcinoGENOMICS project. carcinoGENOMICS was comprised of 20  research organizations representing the pharmaceutical industry as well as leading academic institutions from across Europe. The consortium developed a series of in vitro tests representative of various modes of carcinogenic action for the major target organs liver, lung, and kidney. This approach enables efficient assessment of a high number of compounds as required under  REACH, the European Community Regulations on chemicals and their safe use.  Moreover, this testing resulted in best practices required to successfully reduce animal testing while enabling more cost-efficient R&D processes.

"Toxicogenomics  research is generating large amounts of complex omics data and researchers are challenged to make sense of these data," noted Prof. Dr. Jos Kleinjans, scientific director of the Netherlands Toxigenomic Centre, who  is the coordinator  of the carcinoGENOMICS Project. "Genedata Expressionist helps researchers to effectively meet these challenges, by efficiently analyzing high-throughput molecular profiling data" continued Kleinjans. "Moreover, the Genedata team of scientists provides the necessary expertise to ensure the success of ambitious projects such as ours."

Researchers use Genedata Expressionist to assess assay reproducibility and predict compound carcinogenicity. Assays are based on the application of omics technologies (i.e. genome-wide transcriptomics and metabolomics) to robust in vitro systems (rat/human). Phenotypic markers for genotoxic and carcinogenic events are assessed to anchor gene expression modulations, metabolic profiles, and mechanistic pathways. Through extensive biostatistics, literature mining, and analysis of molecular-expression datasets, differential genetic pathways are identified, which are capable of predicting mechanisms of chemical carcinogenesis in vivo. Furthermore, Genedata Expressionist is able to integrate transcriptomics and metabolomics data to provide a holistic understanding of systems biology and build an iterative in silico model of chemical carcinogenesis.

Recently, Genedata also contributed its software solutions to a number of innovative EU-funded, oncology-focused projects, including:

*    NewGeneris - the consortium successfully investigated chemical risks concerning the development of childhood cancer and immune disorders and the role of prenatal exposure to genotoxic chemicals through maternal intake of  food during pregnancy.
*    INCA - the consortium successfully examined the role of chronic viral infections in the development of cancer.

"Genedata is proud to work with some of the  leading scientists and research organizations worldwide who are  fighting some of the most life-threatening diseases," said Dr. Othmar Pfannes, CEO of Genedata. "The know-how and experience gathered in such collaborations continues to drive the advancement of Genedata Expressionist - with the enhancements now available to all licensees of the system."

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Genedata Signs License Agreement with AstraZeneca
Genedata Screener now AstraZeneca’s corporate platform for expediting drug discovery.
Saturday, November 21, 2015
Kymab Implements Genedata Biologics for High-throughput Antibody Discovery
Genedata Biologics™ integrated workflow platform used to increase throughput and automation of Kymab’s transgenic mice-based discovery platforms.
Tuesday, November 17, 2015
Genedata Completes Important Milestone in Collaboration with Bayer Pharma AG
Successful integration of Genedata Profiler™ allows researchers to access, process, analyze and manage petabytes of NGS and other omics data from patients and pre-clinical experiments.
Thursday, September 24, 2015
Merck Serono Chooses Genedata Biologics to Streamline Antibody Discovery Processes
Global deployment of Genedata Biologics across multiple protein therapeutics R&D groups to standardize workflows and improve efficiency.
Thursday, July 23, 2015
Genedata Releases a Breakthrough for Genomic Comparison
Genedata Selector™4.0 provides reference-independent genome sequence comparisons while reducing data processing and analysis time to optimize efficiency and save costs.
Wednesday, July 22, 2015
Genedata Forges Alliance with Intellicyt
Swiss informatics firm Genedata and Intellicyt today announced an alliance to work on cell-based screening in drug discovery.
Thursday, June 18, 2015
Precision Medicine Software Genedata Profiler™ Launched at Bio-IT World
Open, interoperable enterprise platform for patient and compound profiling provides important data management infrastructure for pharma internal R&D processes.
Friday, April 24, 2015
Partner on Innovative Workflow Platform for High-Throughput Cell Line Development
Novel Cell Line Development (CLD) data platform to support the generation and assessment of mammalian production cell lines.
Tuesday, March 17, 2015
Genedata, Bayer Pharma AG Partner on Innovative Workflow Platform for High-Throughput Cell Line Development
Novel Cell Line Development (CLD) data platform to support the generation and assessment of mammalian production cell lines.
Tuesday, March 17, 2015
Genedata Biologics Licensed by Pfizer
Pfizer implements Genedata Biologics to streamline global biopharma R&D processes.
Wednesday, March 04, 2015
Boehringer Ingelheim Selects Genedata Biologics as Antibody Discovery Workflow Platform
Genedata Biologics integrates and streamlines workflows for protein therapeutics R&D groups across multiple Boehringer Ingelheim sites.
Thursday, February 19, 2015
Genedata Highlights Combination Screening and Surface Plasmon Resonance at SLAS 2015
Colloquium and tutorials on Combination Screening and SPR examine Genedata Screener as the platform for all plate-based screening experiments.
Wednesday, February 04, 2015
Takara Bio Selects Genedata Software to Automate and Standardize NGS Data Analysis
Genedata Expressionist® for Genomic Profiling helps Takara Bio to manage, process, and analyze large NGS datasets.
Wednesday, November 05, 2014
Exploring Innovations in SPR & Combination Screening
Genedata customers will discuss innovations in high content imaging, high throughput screening, compound combination screening, and other related topics at User Group Meetings.
Tuesday, August 26, 2014
GSK Implements Genedata Biologics as Antibody Discovery Platform
Genedata Biologics integrates GlaxoSmithKline's Biopharm Discovery workflows across multiple Biopharm R&D groups and sites
Thursday, June 12, 2014
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
The MaxSignal Colistin ELISA Test Kit from Bioo Scientific
Kit can help prevent the antibiotic apocalypse by keeping last resort drugs out of the food supply.
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos